SeaStar Medical Provides Regulatory Update Related to its HDE Application for Pediatric Selective Cytopheretic Device
09 mai 2023 16h05 HE
|
SeaStar Medical Holding Corporation
DENVER, May 09, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
SeaStar Medical Announces Activation of First Clinical Site in Pivotal Trial with Selective Cytopheretic Device in Critically Ill Adults with Acute Kidney Injury
19 avr. 2023 08h00 HE
|
SeaStar Medical Holding Corporation
DENVER, April 19, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical Reports 2022 Financial Results and Provides a Business Update
30 mars 2023 19h23 HE
|
SeaStar Medical Holding Corporation
DENVER, March 30, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...
SeaStar Medical Holding Corporation Closes Initial $3.3 Million Tranche of $9.8 Million Private Placement
16 mars 2023 08h00 HE
|
SeaStar Medical Holding Corporation
DENVER, March 16, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...
SeaStar Medical to Present at the Emerging Growth Virtual Conference on March 22, 2023
15 mars 2023 16h05 HE
|
SeaStar Medical Holding Corporation
DENVER, March 15, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...
SeaStar Medical’s Selective Cytopheretic Device to be Featured at the 5th Chronic Kidney Disease Drug Development Summit
24 févr. 2023 08h05 HE
|
SeaStar Medical Holding Corporation
DENVER, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...
SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury
15 févr. 2023 16h01 HE
|
SeaStar Medical Holding Corporation
The NEUTRALIZE-AKI study will evaluate safety and efficacy of the SCD’s ability to target and neutralize the highly activated proinflammatory neutrophils and monocytes that drive hyperinflammation ...
SeaStar Medical to Hold Business Update Conference Call on February 15, 2023
14 févr. 2023 16h05 HE
|
SeaStar Medical Holding Corporation
DENVER, Feb. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (Nasdaq: ICU), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital...
SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury
09 févr. 2023 08h19 HE
|
SeaStar Medical Holding Corporation
Patient enrollment in pivotal clinical study expected to begin in March DENVER, Feb. 09, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (Nasdaq: ICU), a medical device company developing proprietary...
SeaStar Medical to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023
31 janv. 2023 08h00 HE
|
SeaStar Medical Holding Corporation
DENVER, Jan. 31, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (Nasdaq: ICU), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital...